<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10099">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133105</url>
  </required_header>
  <id_info>
    <org_study_id>2013-000986-36</org_study_id>
    <secondary_id>2013-000986-36</secondary_id>
    <nct_id>NCT02133105</nct_id>
  </id_info>
  <brief_title>Levosimendan Versus Dobutamine for Renal Function in Heart Failure</brief_title>
  <acronym>ELDOR</acronym>
  <official_title>Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <authority>Sweden: Medicinal Products Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although inotropes have a favorable effect on central hemodynamics in patients with heart
      failure, their effect on renal hemodynamics is incompletely defined. The purpose of this
      study is to evaluate the efficacy of a 75 min intravenous infusion of levosimendan compared
      to a 75 min infusion of dobutamine on renal hemodynamics and function in patients with
      chronic heart failure and signs of cardiorenal syndrome. The investigators hypothesis is
      that patients treated with levosimendan will show greater increases in renal blood flow and
      glomerular filtration rate (GFR) than those treated with dobutamine.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in renal blood flow</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Para-aminohippuric acid (PAH) infusion clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glomerular filtration rate</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Chrome-ethylenediaminetetraacetic acid (EDTA) infusion clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in renal vascular resistance</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Renal blood flow divided by the difference between renal arterial pressure and renal venous pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central hemodynamics</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Right atrial pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure, mean arterial pressure, cardiac output, pulmonary vascular resistance and systemic vascular resistance measured with a pulmonary artery thermodilution catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal oxygen consumption and oxygen extraction</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oxygen consumption: Renal blood flow multiplied by arterial-renal venous oxygen difference.
Oxygen extraction: Ratio of renal oxygen consumption to renal oxygen delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in filtration fraction</measure>
    <time_frame>75 min minus baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ratio of glomerular filtration rate to renal plasma flow</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dobutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dobutamine</intervention_name>
    <arm_group_label>Dobutamine</arm_group_label>
    <other_name>Dobutrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written, signed and dated informed consent

          -  Male and Female subjects ≥18 years of age

          -  Chronic congestive heart failure scheduled for right sided cardiac catheterization

          -  Left ventricular ejection fraction ≤ 40% determined by echocardiography

          -  Elevation of N Terminal-proBNP ≥ 500 ng/L

          -  Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)

        Exclusion Criteria:

          -  Acute heart failure, untreated

          -  Systolic blood pressure &lt; 80 mmHg

          -  Tachycardia above 100 bpm

          -  Angina Canadian Cardiovascular Society (CCS) class III or higher

          -  Aortic stenosis

          -  Hypertrophic cardiomyopathy

          -  Restrictive cardiomyopathy

          -  The presence of kidney disease diagnosed before heart failure

          -  Administration of radiographic contrast &lt; 1 week

          -  Radiographic contrast allergy

          -  In the Investigator's opinion, the patient has a clinically significant disease that
             could be adversely      affected by study participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristjan Karason, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Department of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Inotropic drugs</keyword>
  <keyword>Levosimendan</keyword>
  <keyword>Dobutamine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Simendan</mesh_term>
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
